[go: up one dir, main page]

MX2009008767A - Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacuna anti-gripal. - Google Patents

Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacuna anti-gripal.

Info

Publication number
MX2009008767A
MX2009008767A MX2009008767A MX2009008767A MX2009008767A MX 2009008767 A MX2009008767 A MX 2009008767A MX 2009008767 A MX2009008767 A MX 2009008767A MX 2009008767 A MX2009008767 A MX 2009008767A MX 2009008767 A MX2009008767 A MX 2009008767A
Authority
MX
Mexico
Prior art keywords
increasing
lactobacillus casei
influenza vaccine
protection provided
vaccine
Prior art date
Application number
MX2009008767A
Other languages
English (en)
Inventor
Sandrine Samson-Villeger
Raphaelle Bourdet-Sicard
Original Assignee
Gervais Danone Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone Sa filed Critical Gervais Danone Sa
Publication of MX2009008767A publication Critical patent/MX2009008767A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La invención se refiere a la utilización de Lactobacillus casei en las composiciones administrables por vía oral para reforzar la protección contra la grupa después de la vacunación antigripal, al potencializar la respuesta humoral inducida por esa vacuna.
MX2009008767A 2007-02-16 2008-02-13 Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacuna anti-gripal. MX2009008767A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0701140A FR2912657B1 (fr) 2007-02-16 2007-02-16 Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale.
PCT/FR2008/000181 WO2008129148A2 (fr) 2007-02-16 2008-02-13 Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale

Publications (1)

Publication Number Publication Date
MX2009008767A true MX2009008767A (es) 2009-10-12

Family

ID=38508753

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008767A MX2009008767A (es) 2007-02-16 2008-02-13 Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacuna anti-gripal.

Country Status (16)

Country Link
US (1) US8349315B2 (es)
EP (1) EP2120590B1 (es)
JP (1) JP2010518151A (es)
KR (1) KR20090115960A (es)
CN (1) CN101918013A (es)
AR (1) AR065362A1 (es)
AT (1) ATE530070T1 (es)
BR (1) BRPI0807649A2 (es)
CA (1) CA2678004A1 (es)
ES (1) ES2378052T3 (es)
FR (1) FR2912657B1 (es)
MX (1) MX2009008767A (es)
PL (1) PL2120590T3 (es)
RU (1) RU2470994C2 (es)
WO (1) WO2008129148A2 (es)
ZA (1) ZA200905551B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2937252B1 (fr) * 2008-10-17 2011-05-20 Pf Medicament Association d'un extrait de sureau et d'une souche de l. paracasei.
KR101806435B1 (ko) * 2010-10-15 2017-12-07 시에이치알. 한센 에이/에스 면역보강제
WO2014038929A1 (en) 2012-09-07 2014-03-13 N.V. Nutricia Probiotics for producing antiviral factors
CA2921820C (en) * 2013-08-26 2021-10-12 Meiji Co., Ltd. Antibody titer-increasing agent using lactic acid bacterium
WO2018220416A1 (en) * 2017-05-31 2018-12-06 Compagnie Gervais Danone Lactobacillus paracasei strain capable of improving the immune response to a viral-bacterial coinfection
US20240408154A1 (en) * 2021-11-02 2024-12-12 Kabushiki Kaisha Yakult Honsha Enhancer of number of tcr clones

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1289984B1 (it) * 1997-02-27 1998-10-19 Proge Farm Srl Ceppi di lattobacilli utili nel trattamento di disfunzioni del sistema gastrointestinale
FR2809312B1 (fr) * 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
WO2006124630A2 (en) * 2005-05-13 2006-11-23 New England Medical Center Hospitals, Inc. Compositions and methods for enhancing the efficacy of vaccines

Also Published As

Publication number Publication date
ES2378052T3 (es) 2012-04-04
BRPI0807649A2 (pt) 2014-06-10
RU2009134520A (ru) 2011-03-27
WO2008129148A2 (fr) 2008-10-30
CN101918013A (zh) 2010-12-15
FR2912657A1 (fr) 2008-08-22
ATE530070T1 (de) 2011-11-15
US8349315B2 (en) 2013-01-08
WO2008129148A3 (fr) 2009-02-12
EP2120590A2 (fr) 2009-11-25
FR2912657B1 (fr) 2009-04-17
CA2678004A1 (fr) 2008-10-30
US20100129334A1 (en) 2010-05-27
KR20090115960A (ko) 2009-11-10
EP2120590B1 (fr) 2011-10-26
AR065362A1 (es) 2009-06-03
JP2010518151A (ja) 2010-05-27
ZA200905551B (en) 2010-05-26
RU2470994C2 (ru) 2012-12-27
PL2120590T3 (pl) 2012-05-31

Similar Documents

Publication Publication Date Title
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
GEP20227397B (en) Inhibitors of influenza viruses replication
MX2010004576A (es) Derivados de pirimidina novedosos.
IL186611A0 (en) Vaccine against pandemic strains of influenza viruses
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
IN2012DN02736A (es)
MX2013004190A (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
MX2011008171A (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
JO2892B1 (en) CYP inhibitors 17
MX2013008737A (es) Formas de dosificacion oral para tasocitinib que comprende liberacion modificada.
TW200942524A (en) Novel aminomethyl benzene derivatives
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
WO2008130678A3 (en) Rosuvastatin intermediates and process for the preparation of rosuvastatin
IN2012DN03182A (es)
MX348823B (es) Formulaciones estables de linaclotida.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
TW200942530A (en) Pyridine compounds
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2009008767A (es) Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacuna anti-gripal.
MX342898B (es) Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
TN2009000510A1 (en) Extended release formulation of nevirapine
BR112012024708A2 (pt) composição de compostos orgânicos
MX339619B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration